We should focus more on finding therapeutic targets for the non-inflammatory damage in MS – Yes

Remyelination Trials

“…Therefore, the therapeutic development focus is now shifting toward the repair of damage, neuroprotection, and, potentially, restoration of functional deficit. 1 …”

“…Therefore, the therapeutic development focus is now shifting toward the repair of damage, neuroprotection, and, potentially, restoration of functional deficit. 1 Neuroaxonal loss is believed to underpin the progressive disability that characterizes MS. Although focal inflammatory demyelination is a principal cause of acute axonal transection and subsequent axonal degeneration, the gradual attrition of permanently demyelinated axons may also contribute to tissue damage, particularly in the progressive phase of the disease.…”